ReviewJournal of Zhejiang University. Science. B2013
Induced pluripotent stem cells: origins, applications, and future perspectives.
Review in Journal of Zhejiang University. Science. B, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Quality and Regulatory Requirements for the Manufacture of Master Cell Banks of Clinical Grade iPSCs: The EU and USA Perspectives.Stem cell reviews and reports · 2025Review
- Future perspectives: advances in bone/cartilage organoid technology and clinical potential.Biomaterials translational · 2024Review
- From cells to organs: progress and potential in cartilaginous organoids research.Journal of translational medicine · 2023Review
- Scalable Generation of Nanovesicles from Human-Induced Pluripotent Stem Cells for Cardiac Repair.International journal of molecular sciences · 2022Article
- Medicine and health of 21st Century: Not just a high biotech-driven solution.NPJ genomic medicine · 2022Review
- Pancreatic Transdifferentiation Using β-Cell Transcription Factors for Type 1 Diabetes Treatment.Cells · 2022Review
- Review
- Improved Isolation and Culture of Urine-Derived Stem Cells (USCs) and Enhanced Production of Immune Cells from the USC-Derived Induced Pluripotent Stem Cells.Journal of clinical medicine · 2020Article
- Comparative RNAi Screens in Isogenic Human Stem Cells Reveal SMARCA4 as a Differential Regulator.Stem cell reports · 2019Article
- HLA and Histo-Blood Group Antigen Expression in Human Pluripotent Stem Cells and their Derivatives.Scientific reports · 2017Article
- Induced pluripotent stem cell: A headway in reprogramming with promising approach in regenerative biology.Veterinary world · 2017Review
- EpEX/EpCAM and Oct4 or Klf4 alone are sufficient to generate induced pluripotent stem cells through STAT3 and HIF2α.Scientific reports · 2017Article
- Directed differentiation of human iPSC into insulin producing cells is improved by induced expression of PDX1 and NKX6.1 factors in IPC progenitors.Journal of translational medicine · 2016Article
- Stem Cells in Neurotoxicology/Developmental Neurotoxicology: Current Scenario and Future Prospects.Molecular neurobiology · 2016Review
- Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases.Molecular neurobiology · 2015Review
- Applications of Induced Pluripotent Stem Cells in Studying the Neurodegenerative Diseases.Stem cells international · 2015Review
- Stem Cells in Skeletal Tissue Engineering: Technologies and Models.Current stem cell research & therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Embryonic stem (ES) cells are widely used for different purposes, including gene targeting, cell therapy, tissue repair, organ regeneration, and so on. However, studies and applications of ES cells are hindered by ethical issues regarding cell sources. To circumvent ethical disputes, great efforts have been taken to generate ES cell-like cells, which are not derived from the inner cell mass of blastocyst-stage embryos. In 2006, Yamanaka et al. first reprogrammed mouse embryonic fibroblasts into ES cell-like cells called induced pluripotent stem (iPS) cells. About one year later, Yamanaka et al. and Thomson et al. independently reprogrammed human somatic cells into iPS cells. Since the first generation of iPS cells, they have now been derived from quite a few different kinds of cell types. In particular, the use of peripheral blood facilitates research on iPS cells because of safety, easy availability, and plenty of cell sources. Now iPS cells have been used for cell therapy, disease modeling, and drug discovery. In this review, we describe the generations, applications, potential issues, and future perspectives of iPS cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.